Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof

Patent metadata

Field	Value
Publication number	US-12226479-B2
Application number	US-201816612485-A
Country	US
Kind code	B2
Filing date	May 11, 2018
Priority date	May 11, 2017
Publication date	Feb 18, 2025
Grant date	Feb 18, 2025

Abstract

The subject matter disclosed herein is generally directed to CD8+ tumor infiltrating lymphocytes comprising gene signatures associated with response to immunotherapy treatment. Moreover, the subject matter disclosed herein is generally directed to methods and compositions for use of the gene signatures. Specifically, disclosed herein are gene signatures associated with response to checkpoint blockade therapy and immune cell subtypes characterized by said gene signatures. Further disclosed are methods of using said gene signatures and immune cell subtypes. Further disclosed are pharmaceutical compositions comprising populations of CD8+ TILs enriched for a specific subtype.

First claim

What is claimed is:

1. A method of treating melanoma in a checkpoint blockade (CPB) therapy non-responder subject in need thereof comprising administering polyoxometalate-1 (POM-1) and an anti-T-cell immunoglobulin and mucin-domain containing-3 (TIM3) monoclonal antibody to the subject, wherein the subject expresses a checkpoint blockade (CPB) therapy non-responder gene signature in CD8 + tumor infiltrating lymphocytes (TILs), said CPB therapy non-responder gene signature comprising ENTPD1 (CD39) and HAVCR2 (TIM3), wherein the TIM3 monoclonal antibody is an inhibitor of TIM3 activity, and wherein the response is synergistic.

2. The method of claim 1 , wherein the checkpoint blockade comprises anti-PD1.

3. The method of claim 1 , further comprising detecting in single CD8+ T cells obtained from the subject ENTPD1 (CD39) and HAVCR2 (TIM3), and treating the subject if ENTPD1 (CD39) and HAVCR2 (TIM3) are detected in the single CD8+ T cells.

4. The method of claim 3 , wherein CD39 and TIM3 are detected by immunofluorescence.

5. The method of claim 1 , wherein said CPB therapy non-responder gene signature further comprises one or more genes selected from the group consisting of CCL3, CD38, PDCD1, SNAP47, VCAM1, FASLG, SIRPG, MYO7A, FABP5, NDUFB3, UBE2F, SNRPD1, LAG3, CXCR6, CXCL13, TNFRSF18, CTLA4, TNFRSF9, GEM, NAB1, DFNB31, CADM1, LAYN, RDH10, FAM3C, AFAP1L2, KIR2DL4, MTSS1, ETV1, GOLIM4, LGALS1, EPSTI1, WARS, PLEK, LGALS3, MT2A, GBP1, PLSCR1, CCR5, GSTO1, ANXA5, GLUL, PYCARD, TYMP, IFI6, VAMP5, PRDX3, LGALS9, BATF, PTTG1, TRAFD1, PTPN6, SKA2, LSM2, NMI, IFI35, MTHFD1, IFI27L2, MCM5, STMN1, ID3, RGS3, and FIBP.

Assignees

• Massachusetts Gen Hospital
• Broad Inst Inc

Inventors

• Sade-Feldman Moshe
• Yizhak Keren
• Getz Gad
• Hacohen Nir

Classifications

• G01N33/575

  for cancer · CPC title

• A61K40/4271

  Melanoma antigens · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K2239/57

  Skin; melanoma · CPC title